Beyond weight loss: what GLP-1 trials show for your heart, kidneys, sleep, and liver

For most of their history, GLP-1s were diabetes drugs that happened to cause weight loss. In the last two years, a run of large clinical trials turned them into something bigger. The FDA has now approved these medications to treat or prevent problems in four different organ systems, and the evidence behind each one is worth understanding, along with the fine print that the headlines skip.

Heart: about 20% fewer cardiovascular events

The trial that changed the conversation was SELECT. It enrolled adults with overweight or obesity and established cardiovascular disease, but without diabetes, and gave them semaglutide 2.4 mg (Wegovy) or placebo. The result: a roughly 20% reduction in major adverse cardiovascular events, meaning heart attack, stroke, and cardiovascular death (NEJM, 2023).

On March 8, 2024, the FDA approved Wegovy to reduce that cardiovascular risk, making it the first weight-management medication ever approved to prevent heart events. That approval is also why Medicare, which cannot pay for weight loss alone, can cover a GLP-1 when it is prescribed for an approved condition like heart disease.

Kidneys: 24% fewer major kidney and heart events

The FLOW trial tested semaglutide in a different group: 3,533 adults with type 2 diabetes and chronic kidney disease. Weekly semaglutide cut the combined risk of major kidney events, cardiovascular events, and death from any cause by 24%, and slowed the loss of kidney function, over a median 3.4 years (NEJM, 2024).

On January 28, 2025, the FDA approved Ozempic (the diabetes brand of semaglutide) to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and CKD. Note the brand: this approval is Ozempic, in diabetes, not Wegovy in weight loss.

Sleep apnea: severity cut by up to nearly two-thirds

Sleep apnea is closely tied to obesity, and the SURMOUNT-OSA trial tested tirzepatide (Zepbound) in adults with moderate-to-severe obstructive sleep apnea and obesity. Tirzepatide significantly reduced the apnea-hypopnea index, the standard measure of how many times an hour breathing stops or shallows, by up to nearly two-thirds, along with improvements in weight, blood pressure, and sleep-related quality of life (NEJM, 2024).

On December 20, 2024, the FDA approved Zepbound for moderate-to-severe OSA in adults with obesity. It was the first medication ever approved to treat sleep apnea, a condition that until then was managed mainly with CPAP machines and surgery.

Liver: steatohepatitis resolved in most treated patients

The newest frontier is the liver. MASH (metabolic dysfunction-associated steatohepatitis, formerly called NASH) is a fatty-liver disease that can progress to scarring and cirrhosis. In the ESSENCE trial, adults with MASH and moderate-to-advanced fibrosis took semaglutide 2.4 mg or placebo. At 72 weeks, 62.9% on semaglutide had resolution of steatohepatitis without worsening of fibrosis, versus 34.3% on placebo (NEJM, 2025).

On August 15, 2025, the FDA granted Wegovy accelerated approval for MASH with fibrosis. To be precise: the first drug approved for MASH was resmetirom (Rezdiffra), a different kind of medication, in March 2024. Wegovy is the first GLP-1 to earn a MASH approval, which matters because so many people with obesity also have fatty-liver disease.

The fine print (this part matters)

It is tempting to read the list above as “GLP-1s protect your heart, kidneys, lungs, and liver, so weight loss is almost a bonus.” That is not what the trials showed, and the difference is important:

• Each benefit was studied in a specific population. SELECT was people with existing heart disease. FLOW was people with type 2 diabetes and kidney disease. SURMOUNT-OSA was people with diagnosed sleep apnea. ESSENCE was people with confirmed MASH. If you do not have that condition, the trial did not test you.
• The approvals are split across brands. Wegovy carries the heart and liver approvals; Ozempic carries the kidney and cardiovascular approval in diabetes; Zepbound carries the sleep-apnea approval. Same molecules in some cases, different labels.
• How much is “beyond weight loss” is still debated. Some of the benefit tracks with the weight and metabolic improvement, and some appears to be more direct. Researchers are still untangling it. For you, the practical point is simpler: the drug is approved for the condition, and that is what your prescriber and plan act on.

That last point is also a coverage lever. Because these are approved medical indications, they can unlock insurance, Medicaid, and Medicare coverage that a weight-loss prescription alone cannot. If you have diabetes, heart disease, kidney disease, sleep apnea, or MASH, the covered pathway may run through that diagnosis. We track what each program covers, state by state, on the coverage by state page, and the new Medicare $50 Bridge explainer covers the Medicare side.

What is still being studied

The list is likely to keep growing. Trials are underway or reported in heart failure with preserved ejection fraction (where both semaglutide and tirzepatide have shown benefit in people with obesity), and earlier-stage research is looking at conditions from addiction to Alzheimer’s. Those are not approved uses, and we will not report specific numbers until the trials are published and confirmed.

For now, the plain summary is the one in the trials: for the right patient, a GLP-1 is no longer only a weight drug. If you want to know which version and which pathway fits your situation, start with the am I a candidate? check, compare the real options and costs on /compare, or read how the two leading molecules stack up in Wegovy vs Zepbound. None of this is medical advice, and only your clinician can tell you what is right for you.